ArticleTranslational cancer research2020
ZIP7 (SLC39A7) expression in colorectal cancer and its correlation with clinical prognosis.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Article
- Zinc as a master regulator of intracellular organelle homeostasis.Experimental & molecular medicine · 2026Review
- Metal Ions Within the Neuro-Immune-Tumor Axis.Journal of immunology research · 2026Review
- Zinc Transporters of the LIV-1 Subfamily in Various Cancers: Molecular Insights and Research Priorities for Saudi Arabia.International journal of molecular sciences · 2025Review
- Zinc and its binding proteins: essential roles and therapeutic potential.Archives of toxicology · 2025Review
- SLC30 (ZnT) and SLC39 (ZIP) zinc transporter families: from gatekeepers of zinc homeostasis to promoters of tumorigenesis and targets for clinical therapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a common gastrointestinal malignant tumor that occurs in the colon site and accounts for 9% of the total malignant tumors. Among malignant tumors, its morbidity and mortality respectively rank third and fourth, seriously threatening human health and causing a heavy economic burden on society. ZIP7 (SLC39A7), a kind of zinc transporter, plays a crucial role in the self-renewal of intestinal epithelial cells; however, its role in CRC has not been extensively examined. Therefore, our study aimed to analyze the biological function and expression of this zinc transporter in CRC, along with its correlation with disease activity.
methodsIn this study, 118 cases of colorectal carcinoma tissues, 30 normal tissue samples from adjacent cancer tissues, and 30 normal intestinal mucosa tissue samples from non-intestinal cancer patients were collected in our hospital between February 2014 and February 2015. The expressions of ZIP7 were examined immunohistochemically, and the relationship between ZIP7 expression and the clinical pathological features of CRC were analyzed. After appropriate surgical treatment, the patients accepted a 5-year follow-up for evaluation of their recurrence situation and 5-year survival rate.
resultsImmunohistochemically, out of 80 CRC tissue samples, 67.8% were found to be positive for ZIP7, 55% (44 cases) were strong positives, and 45% (36 cases) were weak positives. There was a striking coherence between the expression of ZIP7, the depth of lymph node metastasis, CRC invasion, and CRC Dukes stage (P<0.05). Subsequent studies indicated that the mortality rate was positively correlated with the staining intensity of ZIP7 (P<0.05), and the Cox proportional hazards model confirmed that ZIP7 is an independent element of prognostic in patients with CRC (RR =3.896; 95% CI: 1.526-9.951; P=0.004).
conclusionsThe high expression of ZIP 7 in epithelial cells is related to the clinical stage and prognosis of CRC and can be utilized as a biomarker to predict the prognosis of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.